NEW YORK (Reuters Health) - Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, lessens lupus-related kidney disease progression in a murine model, researchers report in the September 15th issue of the Journal of Immunology.
Lead investigator Dr. Christopher M. Reilly told Reuters Health that “we have been investigating the role of histone deacetylase inhibitors...for the treatment of lupus nephritis for several years. Our studies have shown beneficial effects in two lupus mouse models.”
In the current study, Dr. Reilly, of Virginia Polytechnic Institute and State University, Blacksburg, and colleagues found that SAHA inhibited production of inflammatory mediators including TNF-alpha and interleukin 6 in mesangial cells -- the principal resident immmunoregulatory cells in the kidney -- from MRL/lpr mice.
Moreover, daily SAHA injections given to MRL/Lpr mice decreased spleen size and decreased renal pathology scores. Serum antibody levels and glomerular IgC and C3 deposition in these animals were similar to those in controls.
Dr. Reilly noted that SAHA is currently in clinical trials for the treatment of specific cancers. He and his colleagues, he added, are now “in the process of completing the necessary steps to begin early clinical trials in humans to determine if SAHA will have the same beneficial effects that we have seen in mice.”
Source: J Immunol 2004;173. [ Google search on this article ]
MeSH Headings:Histones: Nuclear ProteinsCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
